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Abstract
The progesterone receptor (PR) and androgen receptor (AR) belong to the nuclear receptor
superfamily. Two isoforms of PR (A and B) have been identified with different functions. The
expression of AR, each isoform of PR and their involvement in long-term effects on the
endometrium after hormonal replacement therapy (HRT) or tamoxifen (TAM) treatment is not
known. The aims of this study were to determine PR(A+B), PRB and AR distribution by
immunohistochemistry in the macaque (Macaca fascicularis) endometrium. Ovariectomized (OVX)
animals were orally treated continuously for 35 months with either conjugated equine estrogens
(CEE); medroxyprogesterone acetate (MPA); the combination of CEE/MPA; or TAM. Treatment
with CEE/MPA tended to down-regulate PR in the superficial glands, but increased it in the stroma.
TAM treatment increased both the PR and PRB levels in the stroma. Overall, less than 20% of the
cells were positive for the PRB isoform and less variation was observed after steroid treatment.
AR was found in the stroma, mainly distributed in the basal layer of the endometrium in the OVX
and steroid treated groups, but was absent in the TAM treated group. No AR was found in the
glandular epithelium. The present data show that long-term hormone treatment affects the PR
level, and also the ratio between PRA and PRB in the endometrium.
Background
Endometrial carcinomas are one of the most common
cancers in women. Hormone replacement therapy (HRT)
is commonly used for reducing menopausal symptoms,
but is associated with an increased risk of endometrial car-
cinoma [1,2]. Tamoxifen (TAM, estrogen antagonist in
breast, agonist in uterus) is the most commonly used
treatment for women with estrogen receptor (ER) positive
breast cancers but the risk of developing endometrial can-
cer is also increased in those patients [3]. Progesterone
provides a protective effect in HRT by interrupting contin-
ued estrogenic stimulation of the endometrium [4]. The
risk of endometrial cancer has been shown to be de-
creased both after contraceptive treatment with progestin
alone, and after continuous-combined HRT [5,6].
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However, the association between HRT or TAM treatment
and endometrial cancer is still not clearly understood.
The effects of progesterone in humans are mediated by
two specific intracellular progesterone receptor isoforms,
PRA and PRB [7,8]. PRA is a truncated form of PRB, lack-
ing 164 amino acids at the N-terminal region [9]. The PR
isoforms have different biological activities at the tran-
scriptional level [9–11], and the ratio of the receptor iso-
forms can influence the responsiveness of the tissue to
progesterone signals [12,13]. Studies have shown that
PRB is an effective activator of gene transcription [11,14],
and PRA has the ability to suppress the activity of PRB as
well as other steroid hormone receptor family members,
such as AR, glucocorticoid receptor and mineralocorticoid
receptor [11,14,15]. In addition, liganded PRA and PRB
can each suppress E2-stimulated ER activity, with the mag-
nitude of repression dependent on the PR isoform, pro-
gestin ligand, promoter, and cell type [16].
Androgens are generally believed to be hormones of the
male, but androgens also have effects on the female repro-
ductive system [17,18]. Studies have shown that the an-
drogen receptor (AR) is present in the human and
nonhuman primate endometrium, but the results of AR
distribution and regulation are contradictory [19–23]. A
recent study indicated that androgens can antagonize es-
tradiol (E2) action in the macaque and human endometri-
um, and that AR can play a role in the antiproliferative,
"antiestrogenic" effects of antiprogestin in primates [24].
However, the involvement of PR isoforms and AR in the
pathogenesis of endometrial cancer is still not clear. Fe-
male macaques are similar to human beings in many as-
pects of reproductive biology, including the menstrual
cycle [25,26]. The aim of this study was to use the
macaques as a model to compare the protein expression
of PR, PRB and AR in the endometrium after long-term ex-
posure to CEE (conjugated equine estrogens), MPA (me-
droxyprogesterone acetate), CEE+MPA or TAM, in order
to clarify the possible roles of these receptors on the en-
dometrium after long-term treatment with these
compounds.
Material and Methods
Animals
The twenty-five female adult cynomolgus macaques
(Macaca fascicularis) used in this study were imported
from Indonesia to the United States. All the macaques
were 4–6 years old at the beginning of the study. They
were housed in social groups of 4–8 monkeys each in a fa-
cility. Bilateral ovariectomy (OVX) was performed three
months before initiation of hormone treatment. Twenty
monkeys were treated continuously with either 0.625 mg/
day CEE (n = 4); 2.5 mg/day MPA (n = 5); the combina-
tion of CEE + MPA (n = 5); or 20 mg/day TAM (n = 6). Five
animals were without hormone treatment and used as
OVX controls. The compounds were administered in the
diet for 35 months and are expressed as doses equivalent,
on a caloric basis, to those given to women [27]. The ani-
mal studies were approved by the association for the Ad-
vancement and Accreditation of Laboratory Animal Care
and use committee in USA.
Tissue collection
Uterine tissues were collected at the end of the treatment
period, when all the animals were euthanized. Tissues
were trimmed from fat and connective tissues, and fixed
in 4% paraformaldehyde for 24 hours and stored at 4°C
in 70% ethanol. Thereafter tissues were trimmed to 3 mm
in thickness and embedded in paraffin.
Immunohistochemistry
Paraffin sections (5 µm) were used and a standard immu-
nohistochemical technique (avidin-biotin-peroxidase)
was carried out as described before [28] for immunolocal-
ization of PR (A+B), PRB and AR. The different immunos-
taining procedures for each specific primary antibody are
given in table 1. The samples were incubated with the pri-
mary monoclonal antibody, followed by incubation with
the secondary biotinylated horse anti-mouse antibody
(BA-2000, Vector Laboratory, Burlingame, CA, USA) and
an avidin-biotin-peroxidase complex at room tempera-
ture. Replacement of the primary antibody with an equiv-
alent concentration of non-immune mouse IgG was used
for negative controls of PR, PRB and AR, respectively.
The peroxidase substrate diaminobenzidine (DAB) was
used to visualize the immunostaining reaction (SK 4100;
Vector Laboratory, Burlingame, CA, USA). Thereafter the
procedure was as described before [28].
Image analysis and scoring
A Leica microscope and Sony video camera (Park Ridge,
NJ. USA) connected to a computer with an image analysis
software (Leica Imaging System Ltd. Cambridge, UK) were
used to quantitate PR and PRB immunohistochemistry re-
sults, as described previously [28]. In short, by using col-
our discrimination software the total area of positively
stained nuclei (brown) was measured, and expressed as a
percentage of the total area of cell nuclei (brown + blue).
Since AR immunostaining was weak it was not possible to
measure by the image analysis software and therefore the
immunostaining intensity and distribution of AR were as-
sessed semiquantitatively by manual scoring on a two
point scale: - = no staining, + = faint staining, by one ob-
server blinded to treatment.
Statistics
Statistical calculations for the immunohistochemistry re-
sults were performed by ANOVA on ranks (Kruskal-WallisReproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/7
Page 3 of 9
(page number not for citation purposes)
test) and significances were evaluated by Dunn's test (all
compared to all) or Dunnett's test (all compared to con-
trol). Values with different letter designations are signifi-
cantly different (p < 0.05). Values with * are significantly
different (p < 0.05) to OVX control.
Results
Immunohistochemistry showed that PR, PRB and AR
were present in the nuclei of cells in the compartments of
the endometrium (Fig. 1 and 2). The treatments induced
changes of the histological features of the endometrium,
e.g. TAM induced cystic endometrial hyperplasia (Fig.
1i,1j)
PR
Variations were found in PR immunostaining in the su-
perficial endometrium, whereas the immunostaining pat-
tern was less varying in the basal layer. The statistical
analysis was therefore performed on image analyses of the
superficial layer.
In the stromal cells, PR immunoreactivity was low in the
OVX control group (Figure 1a). The immunostaining in-
tensity and number of positive cells increased after treat-
ments (Figure 1c,1e,1g and 1i). In addition, the stromal
cells in the CEE/MPA group showed decidualization, and
PR staining was intense (Fig. 1g). The image analysis
showed an increased level in the CEE/MPA and TAM
groups as compared to the OVX control (Figure 3a).
In the glandular and luminal epithelium, around 30–40%
of the cells were positive in the OVX group (Figure 3b,3c).
In the glands of the superficial layer, a faint PR immuno-
reactivity was observed in the MPA group (Figure 1e, and
figure 3b). Only weak or no immunostaining was ob-
served in glands of the CEE/MPA group (Figure 1g, black
arrow and Figure 3b).
Intense PR immunostaining was observed after TAM treat-
ment in both glandular and luminal epithelium (Fig. 1i
and Fig. 3b,3c). No positive immunostaining was found
in the negative controls (Fig. 1k).
PRB
PRB immunostaining was faint or absent in all compart-
ments of the endometrium and in all studied groups (Fig.
1b,1d,1f,1h,1j). Intensive immunoreactivity of PRB was
observed in the glands of human endometrium from the
proliferative stage of the menstrual cycle (Fig. 1l) and also
in the breast tissue of the CEE treated group of monkeys
(Fig. 1m), which were used as positive controls.
No PRB immunostaining was found in the majority of
stromal cells of the OVX and CEE groups (Figure 1b,1d
and Figure 3d). Around 1–5% of the stroma was weakly
stained for PRB in the MPA, CEE/MPA and TAM groups.
Image analysis results showed an increase after TAM treat-
ment as compared to the OVX group (Fig. 1j and Fig. 3d).
In the luminal epithelium, the PRB immunostaining was
almost absent in the OVX control group. Around 10% of
glandular and luminal epithelia were faintly stained after
TAM treatment (Figure 1j and Figure 3e,3f), as well as in
the glands of the CEE group (Figure 1d and Figure 3e). No
significant differences were found between groups in the
luminal epithelium and in the glands.
PRB/PR
In order to evaluate the relative level of PRA and PRB in
the endometrium, the ratio of PRB/PR are shown in table
2. PRA is by far the most common isoform in macaque en-
dometrium. The highest ratios of PRB/PR were found in
the glands of the CEE group and in all compartments of
the TAM group, suggesting an increased influence of PRB
in these cell types as compared to the other compartments
and treatment groups.
AR
No AR immunostaining was found in the glands in any of
the studied groups. Positive immunostaining was ob-
served in some of the stromal cells, mainly distributed in
the basal layer of the endometrium in the OVX (Fig. 2a),
MPA (Fig. 2b) and CEE/MPA (not shown) treated animals
(Table 3). No staining was present in the endothelial and
smooth muscle cells of the vessels (Figure 2b, arrow). The
TAM treated animals showed no positive AR immunos-
taining (Figure 2c and Table 3). Sweat glands from the
Table 1: Primary antibodies used in the study. Since a specific PRA antibody is not commercially available, the PRA level is difficult to 
measure directly by immunohistochemistry.
Antibody [Specificity] [Working condition] [Sources]
PR (18-0172) N-terminal of Human PR(A+B) Diluted to 1:100 Incubated at RT, 60 min Zymed Lab. Inc., San Francisco, CA
PRB (MA1-411) The 120 kDa of Human PRB Diluted to 1:50 Incubated at RT, 60 min Affinity Bioreagents, Inc., Golden, CO
AR (NCL-AR-2F12) N-terminal of Human AR Diluted to 1:25 Incubated at 4°C, 18 h Novacastra, England UKReproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/7
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Figure 1
Immunohistochemical localization of PR and PRB in the superficial endometrial stroma (Str), glands (G) and luminal epithelium 
(Le). Positive nuclear immunostaining for PR is present in the study groups as shown: OVX (a); CEE (c); MPA (e); CEE /MPA 
(g), and TAM (i). Nuclear PRB immunostaining is shown for: OVX (b); CEE (d); MPA (f); CEE /MPA (h) and TAM (j) groups, 
(bar = 30 µm). A negative control is shown for PR where the first antibody is replaced by mouse IgG (k). Positive controls for 
PRB immunostaining in human endometrium (l) and breast tissue from a CEE treated monkey (m), (bar = 30 µm).Reproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/7
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monkey breast tissue, which was used as positive control,
showed an intense immunostaining for AR (Figure 2d).
Discussion
In vitro studies have shown that PRA and PRB isoforms
can activate different target genes[9]. In vivo studies have
demonstrated that the relative levels of PRA and PRB with-
in endometrial cells may determine the nature and mag-
nitude of their functional responses to progesterone and
estrogen during the menstrual cycle [13]. The results from
the present study show that long-term treatment with the
combination of CEE and MPA to OVX macaques, in-
creased the PR level in the stroma, but reduced PR immu-
noreactivity in the superficial glands. TAM, a partial
estrogen agonist in the uterus, increased the PR levels in
the stroma, with a similar tendency in glandular epitheli-
um. CEE tended to increase the PR level in the stroma and
luminal epithelium, but no significant difference was ob-
served. PRB immunoreactivity was weak in all groups.
Less than 20% of the endometrial cells were positively
stained for PRB in almost all studied samples, however,
TAM increased the stromal PRB level.
It has been demonstrated that estrogen increases, but pro-
gesterone reduces cell proliferation in the endometrium
during the normal menstrual cycle[29], and also in long
term treated OVX macaques[30]. Both PRA and PRB can
be regulated by estrogen and progesterone in the en-
dometrium, and the distinct differences in the relative ex-
pression of PRA and PRB may be associated with different
roles for the isoforms in the different compartments of the
uterus [13]. Pike et al. [6] have reported that the continu-
ous-combined estrogen and progesterone replacement
therapy is not associated with an increased risk of en-
dometrial cancer. The antiproliferative activity of proges-
terone in the endometrium may be the cause of reduced
cancer risk. Although the mechanism of PRA mediated
transdominant inhibition is still unknown, PRA can an-
tagonize ER action [15] and has an ability to suppress the
activity of PRB [11,14]. The ER has important interrela-
tionships with the PR system in modulation of biological
responses. In many estrogen target tissues, e.g. uterus, es-
trogen increases c-fos mRNA levels, cell proliferation, PR
mRNA and protein levels, gap junction formation and
myometrial contractility. These effects are largely antago-
nized by progesterone [31]. These findings give evidence
of interactions and cross talk between members of the
steroid hormone receptor family, which make the mecha-
nism of the receptor activity even more complex.
It has been shown in humans that a relatively high level of
PRA continued to be expressed in the stroma, but not in
epithelial cells of the progestin dependent luteal phase
[32]. It was suggested that the cell-specific effect of proges-
tin indicated a different pathway in the regulation of PR
isoforms in endometrial stromal cells [33]. In the present
study, the up- and down-regulation of PR (mainly PRA)
by MPA/CEE found in the stroma and epithelium,
respectively, is in agreement with a previous study on the
PR mRNA expression [33]. Taken together, the functional
differences of PRA and PRB together with their different
expression pattern in the different compartments of the
endometrium suggest an important role for both isoforms
in the cellular response to steroids. The relative level of
PRA and PRB may determine the expression of specific
genes upon hormonal stimulation. As for ER, PR function
in the epithelium could be regulated by paracrine signals
in the stroma, such as IGF-I and TGF-β4 [34,35].
Studies have shown that endometrial cancers exhibit low-
er PR expression and a predominance of one PR isoform
as compared with the epithelial cells of the normal
Figure 2
AR immunostaining from the basal layer of the endometrium is shown in: OVX (a); MPA (b) and TAM (c) treated animals. As 
positive control for AR immunostaining sweat glands from monkey breast tissue is shown (d), (bar = 20 µm).Reproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/7
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Figure 3
Image analysis scores of positive PR immunoreactivity in superficial stroma (a), superficial glands (b) and luminal epithelium (c). 
PRB immunostaining is shown in superficial stroma (d), superficial glands (e) and luminal epithelium (f). Box and whisker plots 
representing the median value with 50% of all data falling within the box. The whiskers extend to the 5th and 95th percentiles. 
In OVX, MPA and CEE/MPA groups: n = 5, in CEE group n = 4 and in the TAM group n = 6. Values with different letter desig-
nations are significantly different (p < 0.05). Values with * is significantly different (p < 0.05) to OVX control.
Table 2: Ratios of PRB/PR from the median values shown in Fig 2. No significant difference was observed. GE = glandular epithelium. 
LE = luminal epithelium.
Cell type OVX CEE MPA CEE/MPA TAM
Superficial stroma 0.040 0.005 0.060 0.020 0.110
Superficial GE 0.030 0.195 0.050 0.000 0.130
LE 0.020 0.015 0.010 0.055 0.160Reproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/7
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endometrium, where the PR level was high and both PRA
and PRB usually coexpressed [4]. These authors suggest
that loss of coordinated expression of PR isoforms is an
early event in the development of endometrial cancer,
since loss of expression of one PR isoform (A or B) was ob-
served in hyperplasia [4]. In the present study, TAM treat-
ment induced cystic hyperplasia, but the PR level was
increased in the glands and there was a higher ratio of
PRB/ PR in this group. This suggests that the two PR iso-
forms coexist or that the ratio of PRB/PRA is relatively
higher than in the other studied groups. However, PRA is
still the predominant isoform in the epithelium as well as
stroma in this group, since the PRB level is very low, which
is partly consistent with the conclusion made by Arnett-
Mansfield et al. [4].
There is a tendency to increase in stromal PR levels after
CEE treatment in the present study, but not even a
tendency can be seen for PRB. Both PR and PRB are in-
creased by TAM treatment. The conclusion could be that
CEE regulates only PRA, while TAM regulates both PR
subtypes.
The mechanism of TAM-induced carcinogenesis is
thought to be due to its estrogenic actions on the repro-
ductive tract [36]. However, the mechanism that controls
the relative level of PRA and PRB in endometrial cancer
and how TAM induces cancer needs to be further clarified.
Studies have shown that exogenous androgen can have in-
hibitory effects on the female reproductive system
[17,18]. During the menstrual cycle, AR was mainly dis-
tributed in the endometrial stroma of human and
nonhuman primates [23,24,37], and in occasional cells of
the glandular epithelium, but was absent in the vascular
wall [24]. Though we found faint immunostaining of AR
in the macaque endometrium, the stromal distribution
was similar to the previous report [24]. Slayden et al. [24]
have implied that under normal cyclic conditions, stromal
AR levels seem to be up-regulated by E2 and suppressed by
progesterone, which is contradictory to the impression of
the present results on long term treatment. The AR-in-
duced effects of endogenous androgens in the endometri-
um may be mediated mainly via the AR receptor in the
stroma, but not the epithelium. A most interesting finding
by these authors was that AR expression is enhanced in the
endometrial stroma and induced in the glandular epithe-
lium by antiprogestin (RU486) treatment. They suggest
that the increased AR could mediate androgen dependent
antiestrogenic effects induced by antiprogestin [24]. In ad-
dition, we found no positive AR immunostaining in the
TAM treated group, which suggests that TAM may down-
regulate AR expression in the stroma.
We have shown that in the superficial stroma the ERα lev-
el was lower in the CEE/MPA group than in the CEE and
MPA groups [38]. ERβ immunostaining was faint with mi-
nor variations in response to treatments, but increased in
the superficial stroma after MPA treatment. The ratio of
ERβ/ERα increased in superficial stroma and glands after
CEE/MPA treatment, and also in stroma after MPA and
TAM group. Cystic endometrial hyperplasia was observed
in TAM treated animals, in combination with a high level
of ERα protein expression. These data show that long-
term hormone treatment also affects the ERα and ERβ
protein levels in the endometrium, where the balance be-
tween ERα and ERβ seems to be important for the prolif-
erative response to estrogen [38].
The results on ERα [38] showed that there are more cells
positive for ERα than for PR, in all tissues we examined.
Similarities in expression pattern between ERα [38] and
PR are that in the CEE/MPA group both proteins are de-
creased in the epithelium of the superficial glands, where-
as TAM treatment exhibits the highest levels of both ERα
[38] and PR in the luminal epithelium. In the stroma the
combined CEE/MPA treatment reduced the ERα level,
while the PR level was increased [38].
The results of the present study indicate that PR is an im-
portant indicator of hormone responses in endometrium.
The different expression of PRA and PRB might be related
to the responses to hormone therapy and patient out-
Table 3: Manual scoring data of AR immunostaining activity found in basal layer of endometrium. 
Group AR immunostaining
Stroma Gland Luminal epithelium
OVX (n = 5) +, -, -, +, +. -, -, -, -, -. -, -, -, -, -.
CEE (n = 4) +, -, -, -. -, -, -, -. -, -, -, -.
MPA (n = 5) +, +, +, +, +. -, -, -, -, -. -, -, no, -, -.
CEE+MPA (n = 5) +, +, +, +, -. -, -, -, -, +. -, no, -, no, -.
TAM (n = 6) -, -, -, -, -, -. +, -, -, -, -, -. no, -, -, -, -, -.
(-) = no staining, (+) faint staining, no = no luminal epithelium in the sample.Reproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/7
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come. The endometrial hyperplasia found after TAM treat-
ment could be due to the different ratio of PRA to PRB in
the endometrium, possibly in combination with the in-
creased ERα dominance after TAM treatment [38]. Long-
term treatment with steroids did not show a different dis-
tribution pattern of AR as compared to the OVX control,
but AR was almost absent in the TAM group as well as in
the CEE group. Further studies are needed to determine
the importance of the interactions among the steroid hor-
mone receptor members (e.g. AR, PRA and PRB, ERα and
ERβ) for proliferative activity in the endometrium and
possible side effects of HRT and TAM therapy.
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